A batch of key monitoring drugs were cleared out of the hospital

Focus on monitoring drugs or being removed from medical institutions Recently, Suzhou Municipal Health and Health Commission issued the Sixth Batch of key monitoring and rational drug use catalogue in Suzhou, which includes 20 varieties, consistent with the national version In the notice, Suzhou Municipal Health and Health Commission pointed out that for the varieties with unreasonable drug use, measures such as rectifying within a time limit, clearing out the drug supply catalogue of the agency in time were taken to promote rational drug use According to the "pharmaceutical representative" news, some people have reported that they have received a notice from the commercial company that the products listed in the list of key monitoring drugs are required to be returned, including the unfinished varieties Recently, the official website of Zhoushan hospital in Zhejiang Province released the public notice of selecting and selecting alternative drugs and excluding drugs from the list of drug centralized purchase and supply catalogue of public medical institutions in Zhoushan City According to the announcement, 68 products have been listed in the catalogue of selected and alternative drugs for centralized procurement and supply, and 10 products have been listed in the catalogue of key monitoring drugs in the city, and have been removed from the catalogue In addition to being excluded from the purchase catalogue, there are also requirements for some departments to gradually stop using key monitoring drugs - a document recording the use of key monitoring drugs in each department of a third-class hospital in Hubei Province shows that there are 31 varieties in the key monitoring drugs catalogue of the hospital, including 8 traditional Chinese medicine injections There is a red list of forms in the document recording the use of key monitoring drugs The departments in these forms are required to gradually stop using the key monitoring varieties It is not difficult to see that this top three hospital is trying to solve the problem that the key monitoring drug use departments are too extensive According to the notice issued by the national health and Health Commission on July 1, 2019, for the key monitored drugs, each medical institution shall establish corresponding management system, strengthen the whole process management of the clinical application of drugs in the catalogue - further standardize the prescription behavior of doctors, take measures such as ranking notification, rectification within a time limit, clearing out the drug supply catalogue of the institution, etc to ensure the compliance Rationale for medication It can be seen that according to the notice of the national health and Health Commission, the measures to eliminate the medical institutions are mainly aimed at the drugs with unreasonable use In recent years, some key monitoring drugs have been removed from medical institutions, which undoubtedly shows that either the monitoring efforts for some key monitoring drugs with large clinical dosage, high drug amount ranking, and extensive drug departments are increasing; or the unreasonable use of some key monitoring drugs is still prominent, forcing medical institutions to use the monitoring trump card Because, in a long period of time after the release of the national version of the directory of key monitoring drugs, most of the key monitoring drugs around the country are restricted use and strengthened supervision to promote their rational use For example, Shanxi health and Health Commission said in the notice on the management of key monitoring drugs that if doctors need to issue 18 key monitoring drugs to patients, they need to apply for consultation and sign by the president in charge before issuing relevant drugs Some insiders said to cypress blue that in addition to being removed from the medical institutions, the transfer out of medical insurance has a greater impact on the key monitoring drugs Some varieties of the market have been greatly affected, some enterprises are very anxious, and some enterprises are trying to make representations On August 20, the State Medical Security Bureau and the Ministry of human resources and social security explicitly mentioned in the notice on printing and distributing: "After special argumentation, it was unanimously decided to transfer out all the key monitored drugs in the national medical insurance drug catalog." In addition, under the item of "clear local authority", the notice proposed: "for class B drugs added according to regulations in the original provincial drug catalog, they should be gradually digested within 3 years In the digestion process, provinces should give priority to adjusting the payment scope of drugs included in the national key monitoring scope " According to the latest financial reports of relevant pharmaceutical companies, sales of many drugs under key monitoring have declined significantly In its third quarter financial report, Haite Bio said that due to the policy adjustment of the pharmaceutical industry and the impact of the market environment, the sales of its main product, rat nerve growth factor for injection (Jinlujie), continued to decline compared with the same period last year In addition, Haite biology also mentioned that rat nerve growth factor for injection is the main source of its sales revenue at present This time, the focus of monitoring may have a greater adverse impact on the company's sales revenue, and the company has begun to adjust its business The third quarter financial report of Lizhu group shows that the sales revenue of rat nerve growth factor for injection in the nerve field of Lizhu group is 307.1 million yuan, down 14.62% year on year; the sales revenue of Shenqifuzheng injection, a product in the field of traditional Chinese medicine, is 669.53 million yuan, down 18.46% year on year.